Cargando…

Molecular Signatures of KRAS-Mutated Lung Adenocarcinoma: Analysis of Concomitant EGFR, ALK, STK11, and PD-L1 Status

BACKGROUND: KRAS mutations are the most common oncogenic driver mutations of non-small cell lung cancer (NSCLC) in the Western world. Mutations of the KRAS gene are most prevalent in the patient population of current and former cigarette smokers. With the recent pivotal approval of a targeted inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Jim, Annunziata, Joseph F, Burns, Ethan, Bernicker, Eric H, Olsen, Randall J, Thomas, Jessica S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Focus Section: Precision Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134433/ https://www.ncbi.nlm.nih.gov/pubmed/35634237 http://dx.doi.org/10.1177/2632010X221102054

Ejemplares similares

Outcomes and prognostic contributors in patients with KRAS mutated non-small cell pulmonary adenocarcinomas: a single institution experience
por: Burns, Ethan A., et al.
Publicado: (2021)

Histopathological Characteristics of Gastrointestinal Stromal Tumors in a Cohort of Vietnamese Patients
por: Nguyen Cuong, Pham, et al.
Publicado: (2020)

A Simple Panel of IDH1 and P53 in Differential Diagnosis Between Low-Grade Astrocytoma and Reactive Gliosis
por: Geramizadeh, Bita, et al.
Publicado: (2021)

Disseminated Cryptococcal Infection in HIV-Infected Patients: A Retrospective Clinicopathological Review of 4 Autopsy Cases
por: Khaba, Moshawa Calvin, et al.
Publicado: (2022)

COVID-19 Pulmonary Pathology, Ventilator-Induced Lung Injury (VILI), or Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)? Healthcare Considerations Arising From an Autopsy Case and Miny-Review
por: Scendoni, Roberto, et al.
Publicado: (2022)

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
por: Lee, Taebum, et al.
Publicado: (2016)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
por: Brcic, Luka, et al.
Publicado: (2016)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
por: Ahn, Jin Woo, et al.
Publicado: (2014)

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases
por: Wang, Victoria E., et al.
Publicado: (2017)

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA
por: Lai, Andrea Z., et al.
Publicado: (2017)

Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer
por: Hunt, Allison L, et al.
Publicado: (2023)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
por: Zhuang, Xibin, et al.
Publicado: (2019)

Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
por: Lee, Boram, et al.
Publicado: (2016)

38081 A Whole Blood Signature of Neutrophil Expression and Adaptive Immune Downregulation Characterizes Sepsis Mortality
por: Giannini, H.M., et al.
Publicado: (2021)

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status
por: Kim, Hyojin, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
por: Lee, Ki-Chang, et al.
Publicado: (2021)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
por: Huang, Ming-Hung, et al.
Publicado: (2022)

Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma
por: Park, Jangchul, et al.
Publicado: (2016)

Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis
por: Cao, Yajuan, et al.
Publicado: (2019)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

Optimizing Tissue Use: A Step-wise Approach to Diagnosing Squamous Cell Lung Carcinoma on Small Biopsies
por: Olazagasti, Coral, et al.
Publicado: (2020)

2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
por: Ascierto, Paolo A., et al.
Publicado: (2015)

Role of STK11 in ALK-positive non-small cell lung cancer
por: Zhou, Wen, et al.
Publicado: (2022)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
por: DONG, YU, et al.
Publicado: (2016)

Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
por: Mishra, Akhilesh, et al.
Publicado: (2023)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
por: Williams, Christopher J.M., et al.
Publicado: (2023)

Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
por: Azoitei, Ninel, et al.
Publicado: (2012)

Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma
por: Klemen, Nicholas D., et al.
Publicado: (2022)

Imaging of synchronous multiple primary lung adenocarcinoma with concomitant EGFR and KRAS mutations: a case report and review of the literature
por: Ma, Jing-Wen, et al.
Publicado: (2021)

Biological Misinterpretation of Transcriptional Signatures in Tumor Samples Can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data
por: Fisher, Natalie C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hjvdbmd0c3feqj0nkv4b7ikks4